Natera is a diagnostics company. Co. operates one segment, the development and commercialization of molecular testing services, applying its proprietary technology in the fields of women's health, oncology and organ health. Co.'s product offerings include: Panorama Non-Invasive Prenatal Test, which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother; Vistara, which is a single-gene mutations screening test performed to identify single-gene disorders; and Horizon Carrier Screening, which determines carrier status for a number of severe genetic diseases that could be passed on to the carrier's children. The NTRA average annual return since 2015 is shown above.
The Average Annual Return on the NTRA average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether NTRA average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NTRA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free NTRA Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
